Life Extension Final Clerance Sale

Osteoporosis References

Disease Prevention and Treatment, 5th edition

The references on this page correspond with the print version of Disease Prevention and Treatment, 5th edition. Since we continuously update the protocols online in response to new scientific developments, readers are encouraged to review the latest versions of the protocols.

  1. Leong KH. Osteoporosis--the need for a paradigm shift. Ann Acad Med Singapore. 1998 Jan;27(1):100-4.
  2. Wylie CD. Setting a standard for a "silent" disease: defining osteoporosis in the 1980s and 1990s. Stud Hist Philos Biol Biomed Sci. 2010 Dec;41(4):376-85.
  3. Clarke BL, Khosla S. Physiology of bone loss. Radiol Clin North Am. 2010 May;48(3):483-95.
  4. Cawthon PM. Gender Differences in Osteoporosis and Fractures. Clin Orthop Relat Res. 2011 Jan 25.
  5. Kawate H, Takayanagi R. [Secondary osteoporosis UPDATE. Treatment of male osteoporosis. Testosterone replacement therapy etc]. Clin Calcium. 2010 May;20(5):744-51.
  6. Nuti R, Merlotti D, Francucci CM, Gennari L. Bone fragility in men: where are we? J Endocrinol Invest. 2010;33(7 Suppl):33-8.
  7. Ahmed LA, Schirmer H, Bjornerem A, Emaus N, Jorgensen L, Stormer J, Joakimsen RM. The gender- and age-specific 10-year and lifetime absolute fracture risk in Tromso, Norway. Eur J Epidemiol. 2009;24(8):441-8. Epub 2009 May 30.
  8. Confavreux CB, Levine RL, Karsenty G. A paradigm of integrative physiology, the crosstalk between bone and energy metabolisms. Mol Cell Endocrinol. 2009 Oct 30;310(1-2):21-9.
  9. Lieben L, Callewaert F, Bouillon R. Bone and metabolism: a complex crosstalk. Horm Res. 2009 Jan;71 Suppl 1:134-8. Epub 2009 Jan 21.
  10. Zhou Z and Xiong WC. RAGE and its ligands in bone metabolism. Front Biosci (Schol Ed). 2011 Jan 1;3:768-76.
  11. Baldini V, Mastropasqua M, Francucci CM, D'Erasmo E. Cardiovascular disease and osteoporosis. J Endocrinol Invest. 2005;28(10 Suppl):69-72.
  12. Abedin M, Tintut Y, Demer LL. Vascular calcification: mechanisms and clinical ramifications. Arterioscler Thromb Vasc Biol. 2004 Jul;24(7):1161-70.
  13. McFarlane SI, Muniyappa R, Shin JJ, Bahtiyar G, Sowers JR. Osteoporosis and cardiovascular disease: brittle bones and boned arteries, is there a link? Endocrine. 2004 Feb;23(1):1-10.
  14. D'Amelio P, Isaia G, Isaia GC. The osteoprotegerin/RANK/RANKL system: a bone key to vascular disease. J Endocrinol Invest. 2009;32(4 Suppl):6-9.
  15. Tanikawa T et al. Advanced glycation end products induce calcification of vascular smooth muscle cells through RAGE/p38 MAPK. J Vasc Res. 2009;46(6):572-80.
  16. Franke S et al. Advanced glycation endproducts influence the mRNA expression of RAGE, RANKL and various osteoblastic genes in human osteoblasts. Arch Physiol Biochem. 2007 Jun;113(3):154-61.
  17. Hein G et al. Advanced glycation end product modification of bone proteins and bone remodelling: hypothesis and preliminary immunohistochemical findings. Ann Rheum Dis. 2006 Jan;65(1):101-4.
  18. Jager M, Wild A, Krauspe R. Osteonecrosis and HELLP-Syndrome. Z Geburtshilfe Neonatol. 2003 Nov-Dec;207(6):213-9.
  19. Howard PA, Barnes BJ, Vacek JL, Chen W, Lai SM. Impact of bisphosphonates on the risk of atrial fibrillation. Am J Cardiovasc Drugs. 2010;10(6):359-67.
  20. Roelofs AJ, Thompson K, Ebetino FH, Rogers MJ, Coxon FP. Bisphosphonates: molecular mechanisms of action and effects on bone cells, monocytes and macrophages. Curr Pharm Des. 2010;16(27):2950-60.
  21. Varenna M, Gatti D. [The role of rank-ligand inhibition in the treatment of postmenopausal osteoporosis]. Reumatismo. 2010 Jul-Sep;62(3):163-71.
  22. Abrahamsen B. Adverse effects of bisphosphonates. Calcif Tissue Int. 2010 Jun;86(6):421-35.
  23. Hanley DA, Cranney A, Jones G, et al. Vitamin D in adult health and disease: a review and guideline statement from Osteoporosis Canada.CMAJ. 2010 Sep 7;182(12):E610-8.
  24. Martin T, Gooi JH, Sims NA. Molecular mechanisms in coupling of bone formation to resorption. Crit Rev Eukaryot Gene Expr. 2009;19(1):73-88.
  25. Body JJ, Bergmann P, Boonen S, et al. Non-pharmacological management of osteoporosis: a consensus of the Belgian Bone Club. Osteoporos Int. 2011 Mar 1. [Epub ahead of print]
  26. de Baat P, Heijboer MP, de Baat C. Development, physiology, and cell activity of bone. Ned Tijdschr Tandheelkd. 2005 Jul;112(7):258-63.
  27. Kanazawa I, Yamaguchi T, Tada Y, Yamauchi M, Yano S, Sugimoto T. Serum osteocalcin level is positively associated with insulin sensitivity and secretion in patients with type 2 diabetes. Bone. 2011 Apr 1;48(4):720-5.
  28. Mitchner NA, Harris ST. Current and emerging therapies for osteoporosis. J Fam Pract. 2009 Jul;58(7 Suppl Osteoporosis):S45-9.
  29. Banfi G, Lombardi G, Colombini A, Lippi G. Bone metabolism markers in sports medicine. Sports Med. 2010 Aug 1;40(8):697-714.
  30. Chang J, Wang Z, Tang E, et al. Inhibition of osteoblastic bone formation by nuclear factor-kappaB. Nat Med. 2009 Jun;15(6):682-9.
  31. Dwyer J. Starting down the right path: nutrition connections with chronic diseases of later life. Am J Clin Nutr. 2006 Feb;83(2):415S-20S.
  32. Cutler WB, Friedmann E, Genovese-Stone E. Prevalence of kyphosis in a healthy sample of pre- and postmenopausal women. Am J Phys Med Rehabil. 1993 Aug;72(4):219-25.
  33. Akhter MP, Alvarez GK, Cullen DM, Recker RR. Disuse-related decline in trabecular bone structure. Biomech Model Mechanobiol. 2010 Aug 4.
  34. Ebeling PR. Idiopathic or hypogonadal osteoporosis in men: current and future treatment options. Treat Endocrinol. 2004;3(6):381-91.
  35. Englund U, Nordstrom P, Nilsson J, et al. Physical activity in middle-aged women and hip fracture risk: the UFO study. Osteoporos Int. 2011 Feb;22(2):499-505.
  36. Gennari L, Merlotti D, Martini G,et al. Longitudinal association between sex hormone levels, bone loss, and bone turnover in elderly men. J Ciin Endocrinol Metab. 2003 Nov;88(11):5327-33.
  37. Clarke BL, Khosla S. Androgens and bone. Steroids. 2009 Mar;74(3):296-305.
  38. Seeman E. The structural basis of bone fragility in men. Bone. 1999 Jul;25(1):143-7.
  39. Hagino H. [Epidemiology of osteoporotic fractures]. Clin Calcium. 2003;13(8):995-1002. [Article in Japanese]
  40. Ducharme N. Male osteoporosis. Clin Geriatr Med. 2010 May;26(2):301-9.
  41. Nakhla AM, Hryb DJ, Rosner W, Romas NA, Xiang Z, Kahn SM. Human sex hormone-binding globulin gene expression- multiple promoters and complex alternative splicing. BMC Mol Biol. 2009 May 5;10:37.
  42. Hofle G, Tautermann G, Saely CH, Drexel H. Sex-hormone-binding globulin is negatively correlated with femoral bone-mineral density in male cardiac-transplant recipients. Wien Klin Wochenschr. 2004 Mar 31;116(5-6):170-5.
  43. Lormeau C, Soudan B, d'Herbomez M, Pigny P, Duquesnoy B, Cortet B. Sex hormone-binding globulin, estradiol, and bone turnover markers in male osteoporosis. Bone. 2004 Jun;34(6):933-9.
  44. Caldwell JD, Jirikowski GF. Sex hormone binding globulin and aging. Horm Metab Res. 2009 Mar; 41(3): 173-82.
  45. Adams JS. "Bound" to work: the free hormone hypothesis revisited. Cell. 2005 Sep 9;122(5):647-9.
  46. Andreassen TK. The role of plasma-binding proteins in the cellular uptake of lipophilic vitamins and steroids. Horm Metab Res. 2006 Apr;38(4):279-90.
  47. Hoppe E, Bouvard B, Royer M, Audran M, Legrand E. Sex hormone-binding globulin in osteoporosis. Joint Bone Spine. 2010 Jul;77(4):306-12.
  48. de Paula FJ, Horowitz MC, Rosen CJ. Novel insights into the relationship between diabetes and osteoporosis. Diabetes Metab Res Rev. 2010 Nov;26(8):622-30.
  49. Hernandez JL, Olmos JM, Pariente E, et al. Metabolic syndrome and bone metabolism: the Camargo Cohort study. Menopause. 2010 Sep-Oct;17(5):955-61.
  50. McClung M. Is altered bone health part of the metabolic syndrome? Menopause. 2010 Sep-Oct;17(5):900-1.
  51. Akin F, Bastemir M, Alkis E, Kaptanoglu B. SHBG levels correlate with insulin resistance in postmenopausal women. Eur J Intern Med. 2009 Mar;20(2):162-7.
  52. Hein G, Weiss C, et al. Advanced glycation end product modification of bone proteins and bone remodelling: Hypothesis and preliminary immunohistochemical findings. Ann Rheum Dis. 2006 Jan;65(1):101–4.
  53. Valcourt U et al. Non-enzymatic glycation of bone collagen modifies osteoclastic activity and differentiation. J Biol Chem. 2007 Feb 23;282(8):5691-703.
  54. Graham LS, Parhami F, Tintut Y, Kitchen CM, Demer LL, Effros RB. Oxidized lipids enhance RANKL production by T lymphocytes: implications for lipid-induced bone loss. Clin Immunol. 2009 Nov;133(2):265-75.
  55. Maziere C, Savitsky V, Galmiche A, et al. Oxidized low density lipoprotein inhibits phosphate signaling and phosphate-induced mineralization in osteoblasts. Involvement of oxidative stress. Biochim Biophys Acta. 2010 Nov;1802(11):1013-9.
  56. Mundy GR. Osteoporosis and inflammation. Nutr Rev. 2007 Dec;65(12 Pt 2):S147-51.
  57. Kawai M, Devlin MJ, Rosen CJ. Fat targets for skeletal health. Nat Rev Rheumatol. 2009 Jul;5(7):365-72.
  58. Bugel S. Vitamin K and bone health in adult humans. Vitam Horm. 2008;78:393-416.
  59. Wada S, Fukawa T, Kamiya S. [Osteocalcin and bone]. Clin Calcium. 2007 Nov; 17(11):1673-7.
  60. Iwamoto J, Takeda T, Sato Y. Role of vitamin K2 in the treatment of postmenopausal osteoporosis. Curr Drug Saf. 2006 Jan;1(1):87-97.
  61. Rezaieyazdi Z, Falsoleiman H, Khajehdaluee M, Saghafi M, Mokhtari-Amirmajdi E. Reduced bone density in patients on long-term warfarin. Int J Rheum Dis. 2009 Jul;12(2):130-5.
  62. Cherniack EP, Levis S, Troen BR. Hypovitaminosis D: a widespread epidemic. Geriatrics. 2008 Apr;63(4): 24-30.
  63. Lips P, Bouillon R, van Schoor NM, et al. Reducing fracture risk with calcium and vitamin D. Clin Endocrinol (Oxf). 2010 Sep;73(3):277-85.
  64. Aydin H, Deyneli O, Yavuz D, et al, Short-term oral magnesium supplementation suppresses bone turnover in postmenopausal osteoporotic women. Biol Trace Elem Res. 2010 Feb;133(2):136-43.
  65. Mizoguchi T, Nagasawa S, Takahashi N, Yagasaki H, Ito M. Dolomite supplementation improves bone metabolism through modulation of calcium-regulating hormone secretion in ovariectomized rats. J Bone Miner Metab. 2005;23(2):140-6.
  66. Kim MH, Bae YJ, Choi MK, Chung YS. Silicon supplementation improves the bone mineral density of calcium-deficient ovariectomized rats by reducing bone resorption. Biol Trace Elem Res. 2009 Jun;128(3):239-47.
  67. Li Z, Karp H, Zerlin A, Lee TY, Carpenter C, Heber D. Absorption of silicon from artesian aquifer water and its impact on bone health in postmenopausal women: a 12 week pilot study. Nutr J. 2010;9:44.
  68. Spector TD, Calomme MR, Anderson SH, et al. Choline-stabilized orthosilicic acid supplementation as an adjunct to calcium/vitamin D3 stimulates markers of bone formation in osteopenic females: a randomized, placebo-controlled trial. BMC Musculoskelet Disord. 2008;Jun 11; 9:85.
  69. Scorei R, Cimpoiasu VM, Iordachescu D. In vitro evaluation of the antioxidant activity of calcium fructoborate. Biol Trace Elem Res. 2005 Nov;107(2):127-34.
  70. Seymour GJ, Ford PJ, Cullinan MP, Leishman S, Yamazaki K. Relationship between periodontal infections and systemic disease. Clin Microbiol Infect. 2007 Oct;13 Suppl 4:3-10.
  71. Ruiz-Ramos M, Vargas LA, et al. Supplementation of ascorbic acid and alpha-tocopherol is useful to preventing bone loss linked to oxidative stress in elderly. J Nutr Health Aging. 2010 Jun;14(6):467-72.
  72. Dhanwal DK, Dennison EM, Harvey NC, Cooper C. Epidemiology of hip fracture: Worldwide geographic variation. Indian J Orthop. 2011 Jan;45(1):15-22.
  73. Golden SH, Robinson KA, Saldanha I, Anton B, Ladenson PW. Clinical review: Prevalence and incidence of endocrine and metabolic disorders in the United States: a comprehensive review. J Clin Endocrinol Metab. 2009 Jun;94(6):1853-78.
  74. Ferrari S. Human genetics of osteoporosis. Best Pract Res Clin Endocrinol Metab. 2008 Oct;22(5):723-35.
  75. Vibert D, Sans A, Kompis M, et al. Ultrastructural changes in otoconia of osteoporotic rats. Audiol Neurootol. 2008;13(5):293-301.
  76. Sioka C, Fotopoulos A, Georgiou A, Xourgia X, Papadopoulos A, Kalef-Ezra JA. Age at menarche, age at menopause and duration of fertility as risk factors for osteoporosis. Climacteric. 2010 Feb;13(1):63-71.
  77. Jeong SH, Choi SH, Kim JY, Koo JW, Kim HJ, Kim JS. Osteopenia and osteoporosis in idiopathic benign positional vertigo. Neurology. 2009 Mar 24;72(12):1069-76.
  78. Vibert D, Kompis M, Hausler R. Benign paroxysmal positional vertigo in older women may be related to osteoporosis and osteopenia. Ann Otol Rhinol Laryngol. 2003 Oct;112(10):885-9.
  79. El Maghraoui A, Ghazi M, Gassim S, Risk factors of osteoporosis in healthy Moroccan men. BMC Musculoskelet Disord. 2010 Jul 5;11:148.
  80. Bredella MA, Torriani M, Ghomi RH, et al. Determinants of bone mineral density in obese premenopausal women. Bone 2011 Apr 1;48(4):748-54.
  81. Kim HY, Choe JW, Kim HK, et al. Negative association between metabolic syndrome and bone mineral density in Koreans, especially in men. Calcif Tissue Int. 2010 May;86(5):350-8.
  82. Vermeer C, Shearer MJ, Zittermann A, et al. Beyond deficiency: potential benefits of increased intakes of vitamin K for bone and vascular health. Eur J Nutr. 2004 Dec;43(6):325-35.
  83. Kiecolt-Glaser JK, Preacher KJ, MacCallum RC, et al. Chronic stress and age-related increases in the proinflammatory cytokine IL-6. Proc Natl Acad Sci U S A. 2003 Jul 22;100(15):9090-5.
  84. Kaplan JR, Manuck SB. Ovarian dysfunction, stress, and disease: a primate continuum. ILAR J. 2004;45(2):89-115.
  85. Berga SL, Loucks TL. The diagnosis and treatment of stress-induced anovulation. Minerva Ginecol. 2005 Feb;57(1):45-54.
  86. Bab I, Yirmiya R. Depression, selective serotonin reuptake inhibitors, and osteoporosis. Curr Osteoporos Rep. 2010 Dec;8(4):185-91.
  87. Diem SJ, Blackwell TL, Stone KL, et al. Use of antidepressants and rates of hip bone loss in older women: the study of osteoporotic fractures. Arch Intern Med. 2007 Jun 25;167(12):1240-5.
  88. Haney EM, Chan BK, Diem SJ, et al. Association of low bone mineral density with selective serotonin reuptake inhibitor use by older men. Arch Intern Med. 2007 Jun 25;167(12):1246-51.
  89. Ofotokun I, Weitzmann MN. HIV-1 infection and antiretroviral therapies: risk factors for osteoporosis and bone fracture. Curr Opin Endocrinol Diabetes Obes. 2010 Dec;17(6):523-9.
  90. Mehler PS, Cleary BS, Gaudiani JL. Osteoporosis in anorexia nervosa. Eat Disord. 2011 Mar;19(2):194-202.
  91. Ewertz M, Jensen AB. Late effects of breast cancer treatment and potentials for rehabilitation. Acta Oncol. 2011 Feb;50(2):187-93.
  92. Lim JS, Kim SB, Bang HY, Cheon GJ, Lee JI. High prevalence of osteoporosis in patients with gastric adenocarcinoma following gastrectomy. World J Gastroenterol. 2007 Dec 28;13(48):6492-7.
  93. Kanis JA, Johansson H, Oden A, McCloskey EV. Assessment of fracture risk. Eur J Radiol. 2009 Sep;71(3):392-7.
  94. Tsuang YH, Sun JS, Chen LT, Sun SC, Chen SC. Direct effects of caffeine on osteoblastic cells metabolism: the possible causal effect of caffeine on the formation of osteoporosis. J Orthop Surg Res. 2006;1:7.
  95. Tucker KL, Morita K, Qiao N, et al. Colas, but not other carbonated beverages, are associated with low bone mineral density in older women: The Framingham Osteoporosis Study. Am J Clin Nutr. 2006 Oct;84(4):936-42.
  96. Matsui T, Yokoyama A, Matsushita S, et al. Effect of a comprehensive lifestyle modification program on the bone density of male heavy drinkers. Alcohol Clin Exp Res. 2010 May;34(5):869-75.
  97. Deruelle P, Coulon C. The use of low-molecular-weight heparins in pregnancy--how safe are they? Curr Opin Obstet Gynecol. 2007 Dec;19(6):573-7.
  98. Walker J. The role of the nurse in the management of osteoporosis. Br J Nurs. 2010 Oct 28-Nov 10;19(19):1243-7.
  99. Azagra R, Roca G, Encabo G, et al. Prediction of absolute risk of fragility fracture at 10 years in a Spanish population: validation of the WHO FRAX tool in Spain. BMC Musculoskelet Disord. 2011;12:30.
  100. Katzman WB, Vittinghoff E, Ensrud K, Black DM, Kado DM. Increasing kyphosis predicts worsening mobility in older community-dwelling women: a prospective cohort study. J Am Geriatr Soc. 2011 Jan;59(1):96-100.
  101. Santos L, Romeu JC, Canhão H, et al. A quantitative comparison of a bone remodeling model with dual-energy X-ray absorptiometry and analysis of the inter-individual biological variability of femoral neck T-score. J Biomech. 2010 Dec;43(16):3150-5.
  102. Smith MR, McGovern FJ, Fallon MA, Schoenfeld D, Kantoff PW, Finkelstein JS. Low bone mineral density in hormone-naïve men with prostate carcinoma. Cancer. 2001 Jun 15;91(12):2238-45.
  103. Gueldner SH, Britton GR, Madhavan G, et al. Ultrasonometric profiling of incidence and risk of osteoporosis in rural women. J Women Aging. 2008;20(1-2):21-30.
  104. Salaffi F, Silveri F, Stancati A, Grassi W. Development and validation of the osteoporosis prescreening risk assessment (OPERA) tool to facilitate identification of women likely to have low bone density. Clin Rheumatol. 2005 Jun;24(3):203-11.
  105. Perez-Castrillon JL, Sagredo MG, Conde R, del Pino-Montes J, de Luis D. OST risk index and calcaneus bone densitometry in osteoporosis diagnosis. J Clin Densitom. 2007 Oct-Dec;10(4):404-7.
  106. Sveinsdóttir H, Olafsson RF. Women's attitudes to hormone replacement therapy in the aftermath of the Women's Health Initiative study. J Adv Nurs. 2006 Jun;54(5):572-84.
  107. Archer DF. Tissue-selective estrogen complexes: a promising option for the comprehensive management of menopausal symptoms. Drugs Aging. 2010 Jul 1;27(7):533-44.
  108. Silverman SL. New selective estrogen receptor modulators (SERMs) in development. Curr Osteoporos Rep. 2010 Sep;8(3):151-3.
  109. Ko SS, Jordan VC. Treatment of osteoporosis and reduction in risk of invasive breast cancer in postmenopausal women with raloxifene. Expert Opin Pharmacother. 2011 Mar;12(4):657-74.
  110. Ohta H. Bazedoxifene as a new-generation SERM. Clin Calcium. 2011 Jan;21(1):34-42.
  111. Tracz MJ, Sideras K, Boloña ER, et al. Testosterone use in men and its effects on bone health. A systematic review and meta-analysis of randomized placebo-controlled trials. J Clin Endocrinol Metab. 2006 Jun;91(6):2011-6.
  112. Isidori AM, Giannetta E, Greco EA, Effects of testosterone on body composition, bone metabolism and serum lipid profile in middle-aged men: a meta-analysis. Clin Endocrinol (Oxf). 2005 Sep;63(3):280-93.
  113. Rhoden EL, Morgentaler A. Risks of testosterone-replacement therapy and recommendations for monitoring. N Engl J Med. 2004 Jan 29;350(5):482-92.
  114. Morgentaler A. Turning conventional wisdom upside-down: Low Serum testosterone and high-risk prostate cancer. Cancer. 2011 Mar 1.
  115. Drake MT, Cremers SC. Bisphosphonate therapeutics in bone disease: the hard and soft data on osteoclast inhibition. Mol Interv. 2010 Jun;10(3):141-52.
  116. Karabulut AB, Gul M, Karabulut E, Kiran TR, Ocak SG, Otlu O. Oxidant and antioxidant activity in rabbit livers treated with zoledronic acid. Transplant Proc. 2010 Nov;42(9):3820-2.
  117. Enjuanes A, Ruiz-Gaspa S, Peris P, et al. The effect of the alendronate on OPG/RANKL system in differentiated primary human osteoblasts. Endocrine. 2010 Apr;37(2):322-8.
  118. Katsumi H, Kusamori K, Sakane T, Yamamoto A. [Development of delivery system of bisphosphonates for the treatment of osteoporosis]. Yakugaku Zasshi. 2010 Sep;130(9):1129-33.
  119. Sedghizadeh PP, Stanley K, Caligiuri M, et al. Oral bisphosphonate use and the prevalence of osteonecrosis of the jaw: an institutional inquiry. J Am Dent Assoc. 2009 Jan;140(1):61-6.
  120. Miranda J. Osteoporosis drugs increase risk for serious heart arrhythmia problems. Presentation Oct. 28, 2008 at CHEST 2008.
  121. Green J, Czanner G, Reeves G, Watson J, Wise L, Beral V. Oral bisphosphonates and risk of cancer of oesophagus, stomach, and colorectum: case-control analysis within a UK primary care cohort. BMJ. 2010; 341:c4444.
  122. Plosker GL, McTavish D. Intranasal salcatonin (salmon calcitonin). A review of its pharmacological properties and role in the management of postmenopausal osteoporosis. Drugs Aging. 1996 May;8(5):378-400.
  123. Henriksen K, Bay-Jensen AC, Christiansen C, Karsdal MA. Oral salmon calcitonin--pharmacology in osteoporosis. Expert Opin Biol Ther. 2010 Nov;10(11):1617-29.
  124. Chanda D, Kumar S, Ponnazhagan S. Therapeutic potential of adult bone marrow-derived mesenchymal stem cells in diseases of the skeleton. J Cell Biochem. 2010 Oct 1;111(2):249-57.
  125. Centeno CJ, Busse D, Kisiday J, Keohan C, Freeman M, Karli D. Increased knee cartilage volume in degenerative joint disease using percutaneously implanted, autologous mesenchymal stem cells. Pain Physician. 2008 May-Jun;11(3):343-53.
  126. Lee K, Kim H, Kim JM, et al. Systemic transplantation of human adipose-derived stem cells stimulates bone repair by promoting osteoblast and osteoclast formation. J Cell Mol Med. 2011 Oct; 15(10):2082-94.
  127. zur Nieden NI. Embryonic stem cells for osteo-degenerative diseases. Methods Mol Biol. 2011;690:1-30.
  128. Nishibe A, Morimoto S, Hirota K, et. al. [Effect of estriol and bone mineral density of lumbar vertebrae in elderly and postmenopausal women]. Nippon Ronen Igakkai Zasshi. 1996 May;33(5):353-9.
  129. Nozaki M, Hashimoto K, Inoue Y et. al. Usefulness of estriol for the treatment of bone loss in postmenopausal women. Nippon Sanka Fujinka Gakkai Zasshi. 1996 Feb;48(2):83-8.
  130. Kika G, Izumi S, et al. Beneficial aspect of oral estriol as hormone replacement therapy: consideration on bone and lipid metabolism. Tokai J Exp Clin Med. 2009 Sep: 34(2): 92-98.
  131. Weiss EP, Shah K, Fontana L, et al. Dehydroepiandrosterone replacement therapy in older adults: 1- and 2-y effects on bone. Am J Clin Nutr. 2009 May;89(5):1459-67. Epub 2009 Mar 25.
  132. Von Muhlen D et al. Effect of dehydroepiandrosterone supplementation on bone mineral density, bone markers, and body composition in older adults: the DAWN trial. Osteoporos Int. 2008 May;19(5):699-707. Epub 2007 Dec 15.
  133. Morabito N, Crisafulli A, Vergara C, et al. Effects of genistein and hormone-replacement therapy on bone loss in early postmenopausal women: a randomized double-blind placebo-controlled study. J Bone Miner Res. 2002 Oct;17(10):1904-12.
  134. Anderson JJ, Anthony MS, Cline JM, Washburn SA, Garner SC. Health potential of soy isoflavones for menopausal women. Public Health Nutr. 1999 Dec;2(4):489-504.
  135. Harkness LS, Fiedler K, Sehgal AR, Oravec D, Lerner E. Decreased bone resorption with soy isoflavone supplementation in postmenopausal women. J Womens Health (Larchmt). 2004 Nov;13(9):1000-7.
  136. Newton KM, LaCroix AZ, Levy L, et al. Soy protein and bone mineral density in older men and women: a randomized trial. Maturitas. 2006 Oct 20;55(3):270-7.
  137. Weaver CM, Martin BR, Jackson GS, et al. Antiresorptive effects of phytoestrogen supplements compared with estradiol or risedronate in postmenopausal women using (41)Ca methodology. J Clin Endocrinol Metab. 2009 Oct;94(10):3798-805.
  138. Sehmisch S, Erren M, Kolios L, et al. Effects of isoflavones equol and genistein on bone quality in a rat osteopenia model. Phytother Res. 2010 Jun;24 Suppl 2:S168-74.
  139. Sehmisch S, Uffenorde J, Maehlmeyer S, et al. Evaluation of bone quality and quantity in osteoporotic mice--the effects of genistein and equol. Phytomedicine. 2010 May;17(6):424-30.
  140. Lee YB, Lee HJ, Kim KS, et al. Evaluation of the preventive effect of isoflavone extract on bone loss in ovariectomized rats. Biosci Biotechnol Biochem. 2004 May;68(5):1040-5.
  141. Ji G, Yang Q, Hao J, et al. Anti-inflammatory effect of genistein on non-alcoholic steatohepatitis rats induced by high fat diet and its potential mechanisms. Int Immunopharmacol. 2011 Feb 12.
  142. Marini H, Bitto A, Altavilla D, et al. Breast safety and efficacy of genistein aglycone for postmenopausal bone loss: a follow-up study. J Clin Endocrinol Metab. 2008 Dec;93(12):4787-96.
  143. Pavese JM, Farmer RL, Bergan RC. Inhibition of cancer cell invasion and metastasis by genistein. Cancer Metastasis Rev. 2010 Sep;29(3):465-82.
  144. Uesugi T, Fukui Y, Yamori Y. Beneficial effects of soybean isoflavone supplementation on bone metabolism and serum lipids in postmenopausal japanese women: a four-week study. J Am Coll Nutr. 2002 Apr;21(2):97-102.
  145. Atteritano M, Mazzaferro S, Frisina A, et al. Genistein effects on quantitative ultrasound parameters and bone mineral density in osteopenic postmenopausal women. Osteoporos Int. 2009 Nov;20(11):1947-54.
  146. Sogabe N, Maruyama R, Baba O, Hosoi T, Goseki-Sone M. Effects of long-term vitamin K(1) (phylloquinone) or vitamin K(2) (menaquinone-4) supplementation on body composition and serum parameters in rats. Bone. 2011 Feb 2.
  147. Rejnmark L, Vestergaard P, Charles P, et al. No effect of vitamin K1 intake on bone mineral density and fracture risk in perimenopausal women. Osteoporos Int. 2006;17(8):1122-32.
  148. Okura T, Kurata M, Enomoto D, et al. Undercarboxylated osteocalcin is a biomarker of carotid calcification in patients with essential hypertension. Kidney Blood Press Res. 2010;33(1):66-71.
  149. Morishita M, Nagashima M, Wauke K, Takahashi H, Takenouchi K. Osteoclast inhibitory effects of vitamin K2 alone or in combination with etidronate or risedronate in patients with rheumatoid arthritis: 2-year results. J Rheumatol. 2008 Mar;35(3):407-13.
  150. Binkley N, Harke J, Krueger D, et al. Vitamin K treatment reduces undercarboxylated osteocalcin but does not alter bone turnover, density, or geometry in healthy postmenopausal North American women. J Bone Miner Res. 2009 Jun;24(6):983-91.
  151. Koitaya N, Ezaki J, Nishimuta M, et al. Effect of low dose vitamin K2 (MK-4) supplementation on bio-indices in postmenopausal Japanese women. J Nutr Sci Vitaminol (Tokyo). 2009 Feb;55(1):15-21.
  152. Bunyaratavej N, Kittimanon N, Jitivirai T, Tongthongthip B. Highly recommended dose of MK4 for osteoporosis. J Med Assoc Thai. 2009 Sep;92 Suppl5:S4-6.
  153. Sato Y, Honda Y, Kaji M, et al. Amelioration of osteoporosis by menatetrenone in elderly female Parkinson’s disease patients with vitamin D deficiency. Bone. 2002 Jul;31(1):114-8.
  154. Yasui T, Miyatani Y, Tomita J, et al. Effect of vitamin K2 treatment on carboxylation of osteocalcin in early postmenopausal women. Gynecol Endocrinol. 2006 Aug;22(8):455-9.
  155. Shiraki M, Itabashi A. Short-term menatetrenone therapy increases gamma-carboxylation of osteocalcin with a moderate increase of bone turnover in postmenopausal osteoporosis: a randomized prospective study. J Bone Miner Metab. 2009;27(3):333-40.
  156. Knapen MH, Schurgers LJ, Vermeer C. Vitamin K2 supplementation improves hip bone geometry and bone strength indices in postmenopausal women. Osteoporos Int. 2007 Jul;18(7):963-72.
  157. Hirao M, Hashimoto J, Ando W, Ono T, Yoshikawa H. Response of serum carboxylated and undercarboxylated osteocalcin to alendronate monotherapy and combined therapy with vitamin K2 in postmenopausal women. J Bone Miner Metab. 2008;26(3):260-4.
  158. Reese AM, Farnett LE, Lyons RM, et al. Low-dose vitamin k to augment anticoagulation control. Pharmacotherapy. 2005;25(12):1746-51.
  159. Atkins G et al. Vitamin K promotes mineralization, osteoblast-to-osteocyte transition, and an anticatabolic phenotype by y-carboxylation-dependent and -independent mechanisms. Am J Physiol Cell Physiol December 2009 vol. 297 no. 6 C1358-C1367
  160. Rubinacci A. Expanding the functional spectrum of vitamin K in bone. Focus on: “Vitamin K promotes mineralization, osteoblast to osteocyte transition, and an anti-catabolic phenotype by y-carboxylation-dependent and -independent mechanisms”. Am J Physiol Cell Physiol December 2009 vol. 297 no. 6 C1336-C1338
  161. Holick MF. Optimal vitamin D status for the prevention and treatment of osteoporosis. Drugs Aging. 2007;24(12):1017-29.
  162. Holick MF. Vitamin D deficiency. N Engl J Med. 2007 Jul 19;357(3):266-81.
  163. Celik C, Altunkan S, Yildirim MO, Akyuz M. Relationship between decreased bone mineral density and subclinical atherosclerosis in postmenopausal women. Climacteric. 2010 Jun;13(3):254-8.
  164. Tremollieres F, Ribot C. Bone mineral density and prediction of non- osteoporotic disease. Maturitas. 2010 Apr;65(4):348-51.
  165. Bischoff-Ferrari HA, Dawson-Hughes B, Staehelin HB, et al. Fall prevention with supplemental and active forms of vitamin D: a meta-analysis of randomised controlled trials. BMJ. 2009;339:b3692.
  166. Pfeifer M, Begerow B, Minne HW, et al. Effects of a long-term vitamin D and calcium supplementation on falls and parameters of muscle function in community-dwelling older individuals. Osteoporos Int. 2009 Feb;20(2):315-22.
  167. Janssen HC, Samson MM, Verhaar HJ. Muscle strength and mobility in vitamin D-insufficient female geriatric patients: a randomized controlled trial on vitamin D and calcium supplementation. Aging Clin Exp Res. 2010 Feb;22(1):78-84.
  168. Bischoff-Ferrari HA. How to select the doses of vitamin D in the management of osteoporosis. Osteoporos Int. 2007 Apr;18(4):401-7.
  169. Aloia JF, Patel M, Dimaano R, et al. Vitamin D intake to attain a desired serum 25-hydroxyvitamin D concentration. Am J Clin Nutr. 2008 Jun;87(6):1952-8.
  170. Dawson-Hughes B, Heaney RP, Holick MF, et al. Estimates of optimal vitamin D status. Osteoporos Int. 2005 Jul;16(7):713-6.
  171. Heaney RP, Armas LA, Shary JR, 25-Hydroxylation of vitamin D3: relation to circulating vitamin D3 under various input conditions. Am J Clin Nutr. 2008 Jun;87(6):1738-42.
  172. Faloon W. Startling Findings About Vitamin D Levels in Life Extension Members. Life Extension Magazine. 2010 Jan;7-14.
  173. Garland CF, French CB, Baggerly LL, Heaney RP. Vitamin d supplement doses and serum 25-hydroxyvitamin d in the range associated with cancer prevention. Anticancer Res. 2011 Feb;31(2):607-11.
  174. Straub DA. Calcium supplementation in clinical practice: a review of forms, doses, and indications. Nutr Clin Pract. 2007 Jun;22(3):286-96.
  175. Ortolani S, Scotti A, Cherubini R. Rapid suppression of bone resorption and parathyroid hormone secretion by acute oral administration of calcium in healthy adult men. J Endocrinol Invest. 2003 Apr;26(4):353-8.
  176. Nordin BE. The effect of calcium supplementation on bone loss in 32 controlled trials in postmenopausal women. Osteoporos Int. 2009 Dec;20(12):2135-43.
  177. Spangler M, Phillips BB, Ross MB, Moores KG. Calcium supplementation in postmenopausal women to reduce the risk of osteoporotic fractures. Am J Health Syst Pharm. 2011 Feb 15;68(4):309-18.
  178. Fonseca JE. Rebalancing bone turnover in favour of formation with strontium ranelate: implications for bone strength. Rheumatology (Oxford). 2008 Jul;47 Suppl 4:iv17-19.
  179. Hamdy NA. Strontium ranelate improves bone microarchitecture in osteoporosis. Rheumatology (Oxford). 2009 Oct;48 Suppl 4:iv9-13.
  180. Przedlacki J. Strontium ranelate in post-menopausal osteoporosis. Endokrynol Pol. 2011 Jan-Feb;62(1):65-72.
  181. Delannoy P, Bazot D, Marie PJ. Long-term treatment with strontium ranelate increases vertebral bone mass without deleterious effect in mice. Metabolism. 2002;51:906–911.
  182. Cesareo R, Napolitano C, Iozzino M. Strontium ranelate in postmenopausal osteoporosis treatment: a critical appraisal. Int J Womens Health. 2010 Aug 9;2:1-6.
  183. Meunier PJ, Roux C, Seeman E, et al. The effects of strontium ranelate on the risk of vertebral fracture in women with postmenopausal osteoporosis. N Engl J Med. 2004 Jan 29;350(5):459-68.
  184. Reginster JY, Felsenberg D, Boonen S et al. Effects of long-term strontium ranelate treatment on the risk of nonvertebral and vertebral fractures in postmenopausal osteoporosis: Results of a five-year, randomized, placebo-controlled trial. Arthritis Rheum. 2008 Jun;58(6):1687-95.
  185. Reginster JY, Seeman E, De Vernejoul MC, et al. (2005). "Strontium ranelate reduces the risk of nonvertebral fractures in postmenopausal women with osteoporosis: treatment of peripheral osteoporosis (TROPOS) study." J Clin Endorinol Metab 90 (5): 2816–22.
  186. Fisch C, Attia M, Dargent F, et al. Preclinical assessment of gastrooesophageal tolerance of the new antiosteoporotic drug strontium ranelate: an endoscopic study in monkeys. Basic Clin Pharmacol Toxicol. 2006 May;98(5):442-6
  187. Cortet B. Use of strontium as a treatment method for osteoporosis. Curr Osteoporos Rep. 2011 Mar;9(1): 25-30.
  188. Le Merlouette M, Adamski H, Dinulescu M, et al. Strontium ranelate-induced DRESS syndrome. Ann Dermatol Venereol. 2011 Feb;138(2):124-28.
  189. Takaoka S, Yamaguchi T, Yano S, et al. The Calcium-sensing Receptor (CaR) is involved in strontium ranelate-induced osteoblast differentiation and mineralization. Horm Metab Res. 2010 Aug;42(9):627-31.
  190. Nielsen SP, Bärenholdt O, Bärenholdt-Schiøler C, et al. Noninvasive measurement of bone strontium. J Clin Densitom. 2004;7(3):262-8.
  191. Emsley, John, The Elements, 3rd edition, Clarendon Press, Oxford, 1998
  192. Nielsen SP, Slosman D, Sorensen OH, et. al. Influence of strontium on bone mineral density and bone mineral content measurements by dual X-ray absorptiometry.J Clin Densitom. 1999 Winter;2(4):371-9.
  193. Barbagallo M, Belvedere M, Dominguez LJ. Magnesium homeostasis and aging. Magnes Res. 2009 Dec;22(4):235-46.
  194. Sojka 1995
  195. Volpe SL, Taper LJ, Meacham S. The relationship between boron and magnesium status and bone mineral density in the human: a review. Magnes Res. 1993 Sep;6(3):291-6.
  196. Scorei RI, Rotaru P. Calcium Fructoborate-Potential Anti-inflammatory Agent. Biol Trace Elem Res. 2011 Jan 28. [Epub ahead of print]
  197. Nielsen FH. Studies on the relationship between boron and magnesium which possibly affects the formation and maintenance of bones. Magnes Trace Elem. 1990;9(2):61-9.
  198. Xu P, Hu WB, Guo X, et al. [Therapeutic effect of dietary boron supplement on retinoic acid-induced osteoporosis in rats]. Nan Fang Yi Ke Da Xue Xue Bao. 2006 Dec;26(12):1785-8.
  199. Calomme M, Geusens P, Demeester N, et al. Partial prevention of long-term femoral bone loss in aged ovariectomized rats supplemented with choline-stabilized orthosilicic acid. Calcif Tissue Int. 2006 Apr; 78(4):227-32.
  200. Kim MH, Bae YJ, Choi MK, et al. Silicon supplementation improves the bone mineral density of calcium-deficient ovariectomized rats by reducing bone resorption. Biol Trace Elem Res. 2009 Jun;128(3):239-47.
  201. Ailinger RL, Braun MA, Lasus H, Whitt K. Factors influencing osteoporosis knowledge: a community study. J Community Health Nurs. 2005 Fall;22(3):135-42.
  202. DP, Inc., Data on file.
  203. Zinnuroglu M, Dincel AS, Kosova F, Sepici V, Karatas GK. Prospective evaluation of free radicals and antioxidant activity following 6-month risedronate treatment in patients with postmenopausal osteoporosis. Rheumatol Int. 2011 Jan 8.
  204. Mehat MZ, Shuid AN, Mohamed N, Muhammad N, Soelaiman IN. Beneficial effects of vitamin E isomer supplementation on static and dynamic bone histomorphometry parameters in normal male rats. J Bone Miner Metab. 2010 Sep;28(5):503-9.
  205. Chuin A, Labonte M, Tessier D, et al. Effect of antioxidants combined to resistance training on BMD in elderly women: a pilot study. Osteoporos Int. 2009 Jul;20(7):1253-8.
  206. Sugiura M, Nakamura M, Ogawa K, et al. Dietary patterns of antioxidant vitamin and carotenoid intake associated with bone mineral density: findings from post-menopausal Japanese female subjects. Osteoporos Int. 2011 Jan;22(1):143-52.
  207. Hall SL, Greendale GA. The relation of dietary vitamin C intake to bone mineral density: results from the PEPI study. Calcif Tissue Int. 1998 Sep;63(3):183-9.
  208. Gabbay KH, Bohren KM, Morello R, Bertin T, Liu J, Vogel P. Ascorbate synthesis pathway: dual role of ascorbate in bone homeostasis. J Biol Chem. 2010 Jun 18;285(25):19510-20.
  209. Shuid AN, Mehat Z, Mohamed N, Muhammad N, Soelaiman IN. Vitamin E exhibits bone anabolic actions in normal male rats. J Bone Miner Metab. 2010 Mar;28(2):149-56.
  210. Ima-Nirwana S, Suhaniza S. Effects of tocopherols and tocotrienols on body composition and bone calcium content in adrenalectomized rats replaced with dexamethasone. J Med Food. 2004 Spring;7(1):45-51.
  211. Trebble TM, Arden NK, Wootton SA, et al. Fish oil and antioxidants alter the composition and function of circulating mononuclear cells in Crohn disease. Am J Clin Nutr. 2004 Nov;80(5):1137-44.
  212. Fernandes G, Bhattacharya A, Rahman M, Zaman K, Banu J. Effects of n-3 fatty acids on autoimmunity and osteoporosis. Front Biosci. 2008;13:4015-20.
  213. Maggio M, Artoni A, Lauretani F, et al. The impact of omega-3 fatty acids on osteoporosis. Curr Pharm Des. 2009;15(36):4157-64.
  214. Farina EK, Kiel DP, Roubenoff R, et al. Protective effects of fish intake and interactive effects of long-chain polyunsaturated fatty acid intakes on hip bone mineral density in older adults: the Framingham Osteoporosis Study. Am J Clin Nutr. 2011 Mar 2.
  215. Sun L, Tamaki H, Ishimaru T, et al. Inhibition of osteoporosis due to restricted food intake by the fish oils DHA and EPA and perilla oil in the rat. Biosci Biotechnol Biochem. 2004 Dec;68(12):2613-5.
  216. Ward WE, Fonseca D. Soy isoflavones and fatty acids: effects on bone tissue postovariectomy in mice. Mol Nutr Food Res. 2007 Jul;51(7):824-31.
  217. Matsushita H, Barrios JA, Shea JE, Miller SC. Dietary fish oil results in a greater bone mass and bone formation indices in aged ovariectomized rats. J Bone Miner Metab. 2008;26(3):241-7.
  218. Salari P, Rezaie A, Larijani B, Abdollahi M. A systematic review of the impact of n-3 fatty acids in bone health and osteoporosis. Med Sci Monit. 2008 Mar;14(3):RA37-44.
  219. Sacco SM, Jiang JM, Reza-Lopez S, Ma DW, Thompson LU, Ward WE. Flaxseed combined with low-dose estrogen therapy preserves bone tissue in ovariectomized rats. Menopause. 2009 May-Jun;16(3):545-54.
  220. Rahman MM, Bhattacharya A, Banu J, Kang JX, Fernandes G. Endogenous n-3 fatty acids protect ovariectomy induced bone loss by attenuating osteoclastogenesis. J Cell Mol Med. 2009 Aug;13(8B):1833-44.
  221. Rahman MM, Bhattacharya A, Fernandes G. Docosahexaenoic acid is more potent inhibitor of osteoclast differentiation in RAW 264.7 cells than eicosapentaenoic acid. J Cell Physiol. 2008 Jan;214(1):201-9.
  222. Kruger MC, Coetzer H, de Winter R, Gericke G, van Papendorp DH. Calcium, gamma-linolenic acid and eicosapentaenoic acid supplementation in senile osteoporosis. Aging (Milano). 1998 Oct;10(5):385-94.
  223. Salari Sharif P, Asalforoush M, Ameri F, Larijani B, Abdollahi M. The effect of n-3 fatty acids on bone biomarkers in Iranian postmenopausal osteoporotic women: a randomized clinical trial. Age (Dordr). 2010 Jun;32(2):179-86.
  224. Shishodia S, Sethi G, Aggarwal BB. Curcumin: getting back to the roots. Ann N Y Acad Sci. 2005 Nov;1056:206-17.
  225. Oh S, Kyung TW, Choi HS. Curcumin inhibits osteoclastogenesis by decreasing receptor activator of nuclear factor-kappaB ligand (RANKL) in bone marrow stromal cells. Mol Cells. 2008 Nov 30;26(5):486-9.
  226. Yang MW, Wang TH, Yan PP, et al. Curcumin improves bone microarchitecture and enhances mineral density in APP/PS1 transgenic mice. Phytomedicine. 2011 Jan 15;18(2-3):205-13.
  227. French DL, Muir JM, Webber CE. The ovariectomized, mature rat model of postmenopausal osteoporosis: an assessment of the bone sparing effects of curcumin. Phytomedicine. 2008 Dec;15(12):1069-78.
  228. Kupisiewicz K, Boissy P, Abdallah BM, et al. Potential of resveratrol analogues as antagonists of osteoclasts and promoters of osteoblasts. Calcif Tissue Int. 2010 Nov;87(5):437-49.
  229. Pearson KJ, Baur JA, Lewis KN, et al. Resveratrol delays age-related deterioration and mimics transcriptional aspects of dietary restriction without extending life span. Cell Metab. 2008 Aug;8(2):157-68.
  230. Song LH, Pan W, Yu YH, Quarles LD, Zhou HH, Xiao ZS. Resveratrol prevents CsA inhibition of proliferation and osteoblastic differentiation of mouse bone marrow-derived mesenchymal stem cells through an ER/NO/cGMP pathway. Toxicol In Vitro. 2006 Sep;20(6):915-22.
  231. Backesjo CM, Li Y, Lindgren U, Haldosen LA. Activation of Sirt1 decreases adipocyte formation during osteoblast differentiation of mesenchymal stem cells. Cells Tissues Organs. 2009;189(1-4):93-7.
  232. Shakibaei M, Buhrmann C, Mobasheri A. Resveratrol-mediated SIRT-1 Interactions with p300 Modulate Receptor Activator of NF-{kappa}B Ligand (RANKL) Activation of NF-{kappa}B Signaling and Inhibit Osteoclastogenesis in Bone-derived Cells. J Biol Chem. 2011 Apr 1;286(13):11492-505.
  233. He X, Andersson G, Lindgren U, Li Y. Resveratrol prevents RANKL-induced osteoclast differentiation of murine osteoclast progenitor RAW 264.7 cells through inhibition of ROS production. Biochem Biophys Res Commun. 2010 Oct 22;401(3):356-62.
  234. Liu ZP, Li WX, Yu B, et al. Effects of trans-resveratrol from Polygonum cuspidatum on bone loss using the ovariectomized rat model. J Med Food. 2005 Spring;8(1):14-9.
  235. Boots AW, Haenen GR, Bast A. Health effects of quercetin: from antioxidant to nutraceutical. Eur J Pharmacol. 2008 May 13;585(2-3):325-37.
  236. Wattel A, Kamel S, Prouillet C, et al. Flavonoid quercetin decreases osteoclastic differentiation induced by RANKL via a mechanism involving NF kappa B and AP-1. J Cell Biochem. 2004 May 15;92(2):285-95.
  237. Yang YJ, Yang ZL, Wang DC, Xiao XC, Li P. [Comparative study on effects of rutin and quercetin on metabolism in osteoblast cells]. Zhong Yao Cai. 2006 May;29(5):467-70.
  238. Prouillet C, Maziere JC, Maziere C, Wattel A, Brazier M, Kamel S. Stimulatory effect of naturally occurring flavonols quercetin and kaempferol on alkaline phosphatase activity in MG-63 human osteoblasts through ERK and estrogen receptor pathway. Biochem Pharmacol. 2004 Apr 1;67(7):1307-13.
  239. Inoue J, Choi JM, Yoshidomi T, Yashiro T, Sato R. Quercetin enhances VDR activity, leading to stimulation of its target gene expression in Caco-2 cells. J Nutr Sci Vitaminol (Tokyo). 2010;56(5):326-30.
  240. Horcajada-Molteni MN, Crespy V, Coxam V, Davicco MJ, Remesy C, Barlet JP. Rutin inhibits ovariectomy-induced osteopenia in rats. J Bone Miner Res. 2000 Nov;15(11):2251-8.
  241. Li H, Miyahara T, Tezuka Y, et al. The effect of kampo forulae on bone resorption in vitro and in vivo. II. Detailed study of berberine. Biol Pharm Bull. 1999 Apr;22(4):391-6.
  242. Li B, Zhu WL, Chen KX. Advances in the study of berberine and its derivatives. Yao Xue Xue Bao. 2008 Aug;43(8):773-87.
  243. Li H, Miyahara T, Tezuka Y, Tran QL, Seto H, Kadota S. Effect of berberine on bone mineral density in SAMP6 as a senile osteoporosis model. Biol Pharm Bull. 2003 Jan;26(1):110-1.
  244. Lee HW, Suh JH, Kim HN, et al. Berberine promotes osteoblast differentiation by Runx2 activation with p38 MAPK. J Bone Miner Res. 2008 Aug;23(8):1227-37.
  245. Xu D, Yang W, Zhou C, Liu Y, Xu B. Preventive effects of berberine on glucocorticoid-induced osteoporosis in rats. Planta Med. 2010 Nov;76(16):1809-13.
  246. Kondo K. Beer and health: preventive effects of beer components on lifestyle-related diseases. Biofactors. 2004;22(1-4):303-10.
  247. Effenberger KE, Johnsen SA, Monroe DG, et al. Regulation of osteoblastic phenotype and gene expression by hop-derived phytoestrogens. J Steroid Biochem Mol Biol. 2005 Sep;96(5):387-99.
  248. Stevens JF, Page JE. Xanthohumol and related prenylflavonoids from hops and beer: to your good health! Phytochemistry. 2004 May;65(10):1317-30.